Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 27;45(4):309-311.
doi: 10.1093/eurheartj/ehad789.

Overnight exposure to high altitude in pulmonary hypertension: adverse events and effect of oxygen therapy

Simon R Schneider  1 , Julian Müller  1 , Meret Bauer  1 , Laura Mayer  1 , Lea Lüönd  1 , Tanja Ulrich  1 , Michael Furian  1 , Aglaia Forrer  1 , Arcangelo Carta  1 , Esther I Schwarz  1 , Konrad E Bloch  1 , Mona Lichtblau  1 , Silvia Ulrich  1
Affiliations

Overnight exposure to high altitude in pulmonary hypertension: adverse events and effect of oxygen therapy

Simon R Schneider et al. Eur Heart J. .
No abstract available

Keywords: High altitude; Hypoxia; Oxygen; Pulmonary hypertension; Pulmonary vascular disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Baseline characteristics of 27 patients with pulmonary vascular disease defined as pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension are shown (left sector, WHO-FC, WHO dyspnoea functional class; PVR, pulmonary vascular resistance; PaO2, partial pressure of oxygen in arterial blood). Adverse events at high altitude (AEHA) including severe hypoxaemia and acute mountain sickness are graphically illustrated (middle sector). The sector on the right reveals the time to AEHA overall (solid black line) and stratified for patients with severe hypoxaemia treated with supplemental oxygen therapy (long dashed orange line) and those with acute mountain sickness without severe hypoxaemia (dotted blue line), with colours corresponding to the illustration in the middle sector. (B) Assessments at 470 and 2500 m are shown stratified for patients without supplemental oxygen therapy at 2500 m (left dark blue bars and whiskers) and patients with severe hypoxaemia AEHA at 2500 m (right orange bars and whiskers). Bars at the left of each of the six subpanels represent means and standard deviations, whiskers represent mean difference and 95% confidence interval. *Significant difference (P < .05) as calculated by a mixed-linear regression model by intervention (2500 vs. 470 m) corrected for the intervention sequence as a fixed effect and subjects as a random effect. SPAP, systolic pulmonary artery pressure assessed from tricuspid regurgitation velocity without adding right atrial pressure by echocardiography
See this image and copyright information in PMC

References

    1. Schneider SR, Mayer LC, Lichtblau M, Berlier C, Schwarz EI, Saxer S, et al. . Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial. ERJ Open Res 2021;7:00314-2021. 10.1183/23120541.00314-2021 - DOI - PMC - PubMed
    1. Schneider SR, Mayer LC, Lichtblau M, Berlier C, Schwarz EI, Saxer S, et al. . Effect of normobaric hypoxia on exercise performance in pulmonary hypertension: randomized trial. Chest 2021;159:757–71. 10.1016/j.chest.2020.09.004 - DOI - PubMed
    1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. . 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43:3618–731. 10.1093/eurheartj/ehac237 - DOI - PubMed
    1. Carta AF, Lichtblau M, Berlier C, Saxer S, Schneider SR, Schwarz EI, et al. . The impact of breathing hypoxic gas and oxygen on pulmonary hemodynamics in patients with pulmonary hypertension. Front Med (Lausanne) 2022;9:791423. 10.3389/fmed.2022.791423 - DOI - PMC - PubMed
    1. Lichtblau M, Furian M, Aeschbacher SS, Bisang M, Ulrich S, Saxer S, et al. . Dexamethasone improves pulmonary hemodynamics in COPD-patients going to altitude: a randomized trial. Int J Cardiol 2019;283:159–64. 10.1016/j.ijcard.2018.12.052 - DOI - PubMed